文献速递白血病

急性髓系白血病强化化疗后早期(4周)死亡预测模型

Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
PubMed 文献 · Am J Hematol · 2021-11-09

该研究基于1980年至2020年接受强化化疗的3728例新诊断AML患者,按3:1分为训练集(2790例)和验证集(938例),识别出年龄、体能状态、高胆红素血症、肌酐升高、高尿酸血症、非CBF及-Y的细胞遗传学异常和肺炎为早期4周死亡的不良预后因素,并在验证集中验证了风险分层。

要点

  • 老年、体能状态差、器官功能障碍、不良细胞遗传学和感染是AML强化化疗早期死亡的关键预测因素。
  • 验证集中低、高、极高危组4周死亡率分别为2%、14%、50%(强化化疗),低强度治疗分别为3%、9%、20%。
  • 风险分层可指导治疗强度选择,避免早期死亡。

核心结论

  • 基于年龄、体能状态、器官功能、细胞遗传学和感染的风险分类可预测AML强化化疗后4周早期死亡,并指导治疗强度选择。

研究设计与样本

  • 回顾性队列研究,纳入1980年8月至2020年5月接受强化化疗(诱导期阿糖胞苷累积剂量≥700 mg/m2)的3728例新诊断AML患者,按3:1分为训练集(2790例)和验证集(938例)。

主要发现

  • 训练集二元逻辑回归识别出年龄较大、体能状态较差、高胆红素血症、肌酐升高、高尿酸血症、非CBF及-Y的细胞遗传学异常和肺炎为早期4周死亡的不良预后因素。
  • 验证集中2000年至2017年接受强化化疗患者的4周死亡率在低、高、极高危组分别为2%、14%、50%。
  • 验证集中低强度治疗的4周死亡率在低、高、极高危组分别为3%、9%、20%。

关键数值与推荐

  • 强化化疗定义为诱导治疗期间阿糖胞苷累积剂量≥700 mg/m2。
  • 训练集2790例,验证集938例;中位年龄55岁(范围15-99岁);442例(12%)为核心结合因子AML。
  • 验证集(2000-2017年治疗患者)强化化疗4周死亡率:低危2%、高危14%、极高危50%;低强度治疗:低危3%、高危9%、极高危20%。

临床怎么用

  • 对拟接受强化化疗的AML患者,评估年龄、体能状态、器官功能(胆红素、肌酐、尿酸)、细胞遗传学异常和感染(肺炎),以进行早期死亡风险分层。
  • 根据风险分层选择治疗强度,高危和极高危患者可能从低强度治疗中获益以避免早期死亡。

局限性

  • 风险模型基于单中心数据,外部适用性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The progress with intensive chemotherapy and supportive care measures has improved survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent development of effective low intensity therapies, an optimal decision on the therapy intensity may improve survival through the avoidance of early mortality. We reviewed the outcome of 3728 patients with newly diagnosed AML who received intensive chemotherapy between August 1980 and May 2020. Intensive chemotherapy was defined as a cumulative cytarabine dose ≥ 700 mg/m2 during induction therapy. We divided the whole cohort into a training and validation group at a 3:1 ratio. The population was divided into a training (2790 patients) and a validation cohort (938 patients). The median age was 55 years (range, 15-99). Among them, 442 patients (12%) had core-binding factor AML. Binary logistic regression identified older age, worse performance status, hyperbilirubinemia, elevated creatinine, hyperuricemia, cytogenetic abnormalities other than CBF and -Y, and pneumonia as adverse prognostic factors for an early 4-week mortality. This risk classification for early mortality was verified in the validation cohort of patients. In the validation cohort of more recently treated patients from 2000 to 2017, the 4-week mortality rates with intensive chemotherapy were 2%, 14%, and 50% in the low-, high-, and very high-risk group, respectively. The mortality rates with low intensity therapies were 3%, 9%, and 20%, respectively. The risk classification guides treatment intensity by the assessment of age, frailty, organ dysfunction, cytogenetic abnormality, and infection to avoid early mortality.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Sasaki K, Kadia T, Begna K, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2021. PMID: 34716921. doi:10.1002/ajh.26395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。